Disease activity return after natalizumab cessation in multiple sclerosis.

Disease activity return after natalizumab cessation in multiple sclerosis.

Item
http://www.wikidata.org/entity/Q38779091
Severe inflammatory disease activity 14 months after cessation of Natalizumab in a patient with Leber's optic neuropathy and multiple sclerosis - a case reportα4-integrin receptor desaturation and disease activity return after natalizumab cessationHalf-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findingsPrediction of natalizumab anti-drug antibodies persistency.Disease reactivation after switching from natalizumab to daclizumab.Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.
P2860

Disease activity return after natalizumab cessation in multiple sclerosis.

Item
http://www.wikidata.org/entity/Q38779091
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Disease activity return after natalizumab cessation in multiple sclerosis.
@en
type
label
Disease activity return after natalizumab cessation in multiple sclerosis.
@en
prefLabel
Disease activity return after natalizumab cessation in multiple sclerosis.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Disease activity return after natalizumab cessation in multiple sclerosis.
@en
P2093
P2860
P304
P31
P356
10.1586/14737175.2016.1168295
P433
P478
P577
P698
P921